KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Solid Tumors With HRAS Alterations|Non Small Cell Lung Cancer (NSCLC)|Colorectal Cancer (CRC)|Pancreatic Ductal Adenocarcinoma (PDAC)|Clear Cell Renal Cell Carcinoma (ccRCC)|Renal Cell Carcinoma (Kidney Cancer)
DRUG: KO-2806|DRUG: Cabozantinib|DRUG: Adagrasib
Rate of dose-limiting toxicities (DLTs), DLTs will be evaluated during the first 28 days of KO-2806 treatment (dose escalation)|Descriptive statistics of adverse events, NCI-CTCAE v5.0, First dose of KO-2806 up to and including 28 days after last dose of KO-2806, or if the patient is lost to follow-up, whichever comes first (dose escalation)|Overall Response Rate (ORR), Assessed per RECIST v1.1, Up to an estimated period of 24 months (dose expansion)
Rate of dose-limiting toxicities (DLTs), DLTs will be evaluated during the first 28 days of KO-2806 treatment (dose expansion)|Descriptive statistics of adverse events, NCI-CTCAE v5.0, First dose of KO-2806 up to and including 28 days after last dose of KO-2806, or if the patient is lost to follow-up, whichever comes first (dose expansion)|Objective Response Rate (ORR), Assessed per RECIST v1.1, Up to an estimated period of 24 months (dose escalation)|Disease control rate (DCR), Assessed per RECIST v1.1, Up to an estimated period of 24 months (dose escalation and expansion)|Duration of response (DoR), Assessed per RECIST v1.1, Up to an estimated period of 24 months (dose escalation and expansion)|Progression-Free Survival (PFS), Assessed per RECIST v1.1, Up to an estimated period of 24 months (dose escalation and expansion)|Overall Survival (OS), Assessed per RECIST v1.1, Up to an estimated period of 24 months (dose escalation and expansion)|AUClast, Area under the curve from time zero to last measurable concentration for KO-2806 (in the absence and presence of food) and combination agent., Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|AUC0-inf, Area under the curve from time zero to infinity post administration for KO-2806 (in the absence and presence of food) and combination agent, Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|Cmax, Maximum plasma concentration (Cmax) of KO-2806 (in the absence and presence of food) and the combination agent, Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|Cmin, Minimum plasma concentration (Cmin) of KO-2806 (in the absence and presence of food) and the combination agent, Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|Tmax, Time to maximal concentration (Tmax) of KO-2806 (in the absence and presence of food) and the combination agent, Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|Estimated terminal elimination rate constant (Î»z), Estimated terminal elimination rate constant of KO-2806 and the combination agent, Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|t1/2, Half-life (t1/2) of KO-2806 (in the absence and presence of food) and the combination agent, Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|CL/F, Total apparent clearance (CL/F) of KO-2806 and the combination agent, Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|Vd/F, Total apparent volume of distribution (Vd/F) of KO-2806 and the combination agent, Cycle 1. Each cycle is 28 days. (Dose escalation and dose expansion).|QTcF, QT interval corrected for heart rate (HR) using Fridericia's formula (QTcF) for KO-2806 monotherapy and in combination, Up to day 7 following first dose of KO-2806 and adagrasib. Dose escalation and dose expansion.|KO-2806 plasma concentration measurements, Up to day 28 following first dose of KO-2806 and adagrasib. Dose escalation and dose expansion.|Amount of KO-2806 excretion in urine, Up to 24 hours following first dose of KO-2806. Dose escalation.|CLr of KO-2806 excretion in urine, Renal clearance of KO-2806 excretion in urine, Up to 24 hours following first dose of KO-2806. Dose escalation.
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.